TOP Financial (TOP)

Search documents
ROSEN, A TOP RANKED LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNM
GlobeNewswire News Room· 2025-05-19 23:40
Core Viewpoint - Rosen Law Firm is reminding investors who purchased Actinium Pharmaceuticals, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on May 26, 2025, for a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Actinium securities between October 31, 2022, and August 2, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6] - The deadline to move the Court to serve as lead plaintiff is May 26, 2025, with the lead plaintiff acting on behalf of other class members [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has been ranked highly for securities class action settlements [4] Group 3: Case Allegations - The lawsuit alleges that during the Class Period, Actinium made false or misleading statements regarding the likelihood of FDA approval for its Iomab-B Biologics License Application [5] - Specific claims include that data from the Sierra Trial was unlikely to meet FDA guidelines, and that positive statements made by Actinium were materially misleading [5]
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Elevance Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ELV
GlobeNewswire News Room· 2025-05-19 23:10
Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Elevance Health, Inc. common stock during the specified Class Period, indicating potential legal issues related to misleading statements made by the company regarding Medicaid costs and premium rates [1][5]. Group 1: Class Action Details - The class action is for investors who purchased Elevance common stock between April 18, 2024, and October 16, 2024, and they may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2][3]. - Investors wishing to serve as lead plaintiff must file a motion with the Court by July 11, 2025 [1][3]. Group 2: Allegations Against Elevance Health - The lawsuit claims that Elevance Health made false or misleading statements about their monitoring of cost trends related to the Medicaid redetermination process, which was not accurately reflected in their financial guidance for 2024 [5]. - It is alleged that the company assured investors that rising Medicaid expenses were adequately accounted for, while in reality, the acuity and utilization of Medicaid members were increasing significantly due to the redetermination process [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].
ROSEN, A TOP RANKED LAW FIRM, Encourages Avis Budget Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAR
GlobeNewswire News Room· 2025-05-19 22:58
Core Viewpoint - Rosen Law Firm is reminding investors who purchased Avis Budget Group, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who purchased Avis Budget securities between February 16, 2024, and February 10, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by June 24, 2025 [3]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, Avis Budget made false and misleading statements regarding its fleet rotation plan, which negatively impacted the value of its vehicles and led to billions in impairment charges [5]. - The claims suggest that Avis Budget's financial and business prospects were overstated, resulting in investor damages when the true information became public [5].
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages SoundHound AI, Inc. Investors to Secure Counsel Before Important May 27 Deadline in Securities Class Action – SOUN, SOUNW
GlobeNewswire News Room· 2025-05-19 19:37
NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SoundHound AI, Inc. (NASDAQ: SOUN, SOUNW) between May 10, 2024 and March 3, 2025, both dates inclusive (the “Class Period”), of the important May 27, 2025 lead plaintiff deadline. SO WHAT: If you purchased SoundHound securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...
IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors
Prnewswire· 2025-05-06 10:00
"IDE849 is a potential first-in-class DLL3 TOP1 ADC, a target antigen that has demonstrated preliminary monotherapy clinical validation in SCLC. In addition, IDE849 aligns with our strategy to develop rational combination therapies, particularly with our potential first-in-class Phase 1 PARG inhibitor IDE161, where we have generated preclinical combination data with TOP1-based ADCs that demonstrates combination synergy and enhanced durability," said Dr. Darrin M. Beaupre, M.D., Ph.D., Chief Medical Officer, ...
TOP RANKED ROSEN LAW FIRM Encourages BigBear.ai Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBAI
GlobeNewswire News Room· 2025-05-04 21:04
Core Viewpoint - Rosen Law Firm is reminding investors who purchased BigBear.ai Holdings, Inc. securities between March 31, 2022, and March 25, 2025, of the June 10, 2025, deadline to become lead plaintiffs in a class action lawsuit [1] Group 1: Class Action Details - A class action lawsuit has been filed against BigBear.ai, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - Investors wishing to serve as lead plaintiffs must file with the court by June 10, 2025 [2] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements for investors, including over $438 million in 2019 and has been ranked highly in securities class action settlements since 2013 [3] Group 3: Case Allegations - The lawsuit alleges that BigBear.ai made false and misleading statements regarding its accounting practices, particularly related to the 2026 Convertible Notes [4] - Specific allegations include deficiencies in accounting review policies, improper accounting for the 2026 Convertible Notes, and the likelihood of needing to restate financial statements [4] - The inaccuracies in financial statements are claimed to have caused investor damages when the true details became public [4]
ROSEN, A TOP RANKED LAW FIRM, Encourages Bakkt Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BKKT
GlobeNewswire News Room· 2025-05-04 19:33
Core Viewpoint - Rosen Law Firm is reminding investors who purchased Bakkt Holdings, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on June 2, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Bakkt securities between March 25, 2024, and March 17, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by June 2, 2025 [2]. - The lawsuit alleges that Bakkt made false or misleading statements regarding its crypto services revenue stability, dependence on a single contract with Webull, and its ability to maintain key client relationships, which misled investors [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise in this area [3].
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Bakkt Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BKKT
GlobeNewswire News Room· 2025-04-30 22:28
Core Viewpoint - Rosen Law Firm is reminding investors who purchased Bakkt Holdings, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on June 2, 2025, and the potential for compensation without out-of-pocket costs [1][2]. Group 1: Class Action Details - Investors who bought Bakkt securities between March 25, 2024, and March 17, 2025, may be eligible to join a class action lawsuit [1][2]. - A class action lawsuit has already been filed, and interested parties must act by the June 2, 2025 deadline to serve as lead plaintiff [2][6]. - The lawsuit alleges that Bakkt made false or misleading statements regarding its crypto services revenue and client relationships, which led to investor damages when the truth was revealed [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen has been recognized as a Titan of Plaintiffs' Bar by Law360, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3].
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Everus Construction Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ECG
GlobeNewswire News Room· 2025-04-30 21:08
NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Everus Construction Group, Inc. (NYSE: ECG) between October 31, 2024 and February 11, 2025, both dates inclusive (the “Class Period”), including investors who held MDU Resources Group, Inc. (“MDU Resources”) common stock as of October 21, 2024 and acquired Everus Construction common stock issued in connection with the spinoff of Everus Construction on or about October 3 ...
ROSEN, A TOP RANKED LAW FIRM, Encourages Treace Medical Concepts, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – TMCI
GlobeNewswire News Room· 2025-04-29 23:08
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Treace Medical Concepts, Inc. (NASDAQ: TMCI) between May 8, 2023 and May 7, 2024, both dates inclusive (the “Class Period”), of the important June 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Treace Medical securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arra ...